Kiromic Biopharma, Inc.
Biotechnology Research
Houston, TX 6,323 followers
Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors
Über uns
Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn. OTCB: KRBP
- Website
-
http://www.kiromic.com
External link for Kiromic Biopharma, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Houston, TX
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2012
- Spezialitäten
- Cancer Research, Tumor Immunology, Cell Culture, Biopharmaceutical, and Nanotechnology
Standorte
-
Primäre
Wegbeschreibung erhalten
7707 Fannin Street
140
Houston, TX 77054, US
Employees at Kiromic Biopharma, Inc.
-
Lucia Piccotti, PhD, EMBA
Senior Director of Strategic Innovation
-
Michael Nagel
President & CEO Vomaris Innovations: Corporate Board Member, Commercializing Breakthrough Medical Technologies through: High-performing Teams |…
-
Leonardo Mirandola, PhD
CSO and Interim COO @ Kiromic Biopharma | Biotech Operations and Strategy
-
Brian Hungerford, CPA CGMA
Board Member, Executive, Consultant, Efficiency Expert, Automation Specialist, Entrepreneur, and Philanthropist
Aktualisierungen
-
Please read about the promising results from the first cohort of three patients in our Deltacel-01 Phase 1 clinical trial at Beverly Hills Cancer Center. "Consistency in safety, tolerability, and disease stability is of paramount importance at this stage of testing, and the data thus far bolster our confidence in Deltacel's potential as a transformative treatment," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “The findings are especially promising considering the robustness of response in the absence of brain metastasis, and the notable reduction in tumor size for the second and the first patient, respectively." #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eVycTBzU
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Kiromic Biopharma, Inc.
8 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 8.0M